Suppr超能文献

KATP通道开放剂可防止缺血再灌注期间细胞溶质钙升高。

KATP-channel openers protect against increased cytosolic calcium during ischaemia and reperfusion.

作者信息

Behling R W, Malone H J

机构信息

Division of Discovery Chemistry, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey 08543-4000, USA.

出版信息

J Mol Cell Cardiol. 1995 Sep;27(9):1809-17. doi: 10.1016/0022-2828(95)90004-7.

Abstract

There is ample evidence that potassium channel openers protect the ischaemic myocardium. Although the protective mechanism is unknown, indirect evidence suggests that potassium channel openers reduce calcium influx during ischaemia which may explain their protective effects. However, recently discovered potassium channel openers such as BMS-180448 are cardioprotective without displaying classical indications of calcium lowering. The current study was designed to provide direct evidence that potassium channel openers delay or prevent increased intracellular free calcium in the myocardium during ischaemia and reperfusion. Cytosolic calcium concentrations were directly measured in perfused rat hearts during global ischaemia by 19F-NMR of the calcium chelator 5F-BAPTA. The cytosolic Ca2+ concentration in vehicle-treated hearts increased from a pre-ischaemia average of 310 +/- 40 nM to 1000 +/- 130 nM during 25 min of ischaemia, followed by partial recovery to 530 +/- 100 nM during 19 min of reperfusion. In contrast, the cytosolic Ca2+ concentration in hearts treated with potassium channel openers BMS-180448 and cromakalim remained low throughout ischaemia, changing from pre-ischaemia averages of 270 +/- 30 nM to 230 +/- 60 nM and from 240 +/- 20 nM to 170 +/- 30 nM during 25 min of ischaemia, respectively. The cytosolic Ca2+ concentrations in these hearts increased to 440 +/- 110 nM in BMS-180448 treated hearts and 290 +/- 60 nM in cromakalim treated hearts during the first 6 min of reperfusion, and were 460 +/- 60 nM for BMS-180448 and 600 +/- 70 nM for after cromakalim 19 min of reperfusion.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

有充分证据表明钾通道开放剂可保护缺血心肌。尽管其保护机制尚不清楚,但间接证据表明钾通道开放剂可减少缺血期间的钙内流,这可能解释了它们的保护作用。然而,最近发现的钾通道开放剂如BMS - 180448具有心脏保护作用,却未表现出典型的降低钙的迹象。本研究旨在提供直接证据,证明钾通道开放剂在缺血和再灌注期间可延迟或防止心肌细胞内游离钙增加。通过钙螯合剂5F - BAPTA的19F - NMR直接测量了整体缺血期间灌注大鼠心脏的胞质钙浓度。在缺血25分钟期间,用载体处理的心脏的胞质Ca2 +浓度从缺血前的平均310±40 nM增加到1000±130 nM,随后在再灌注19分钟期间部分恢复到530±100 nM。相比之下,用钾通道开放剂BMS - 180448和克罗卡林处理的心脏在整个缺血期间胞质Ca2 +浓度保持较低,在缺血25分钟期间分别从缺血前的平均270±30 nM变为230±60 nM以及从240±20 nM变为170±30 nM。在再灌注的前6分钟,BMS - 180448处理的心脏的胞质Ca2 +浓度增加到440±110 nM,克罗卡林处理的心脏增加到290±60 nM,再灌注19分钟后,BMS - 180448为460±60 nM,克罗卡林为600±70 nM。(摘要截短至250字)

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验